Radiation therapy outcomes of patients with pituitary macroadenoma

Khan,Sardar Ali; Shafiq,Waqas; Azmat,Umal; Siddiqi,Ahmed Imran; Alvi,Asim Munir; Ashfaq,Sara; Irfan,Hira; Bakar,Muhammad Abu; Asghar,Kashif

doi:10.3892/br.2022.1594

Radiation therapy outcomes of patients with pituitary macroadenoma

Authors:
- Sardar Ali Khan
- Waqas Shafiq
- Umal Azmat
- Ahmed Imran Siddiqi
- Asim Munir Alvi
- Sara Ashfaq
- Hira Irfan
- Muhammad Abu Bakar
- Kashif Asghar
View Affiliations

Affiliations: Department of Endocrinology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punjab 54000, Pakistan, Department of Cancer Registry and Clinical Data Management, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punjab 54000, Pakistan, Department of Basic Sciences Research, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Punjab 54000, Pakistan
Published online on: December 8, 2022 https://doi.org/10.3892/br.2022.1594
Article Number: 12
Copyright: © Khan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pituitary adenomas are one of the most common benign intracranial tumors, which are normally treated with surgery along with radiation therapy and medication such as dopamine agonist in prolactinoma. The aim of the present study was to evaluate the outcome of patients with pituitary macroadenoma who underwent radiation therapy. For the present retrospective study, a total of 75 patients with pituitary macroadenoma who received radiation therapy were included. Data was acquired from the electronic medical record system of the hospital. Mean ± standard deviation of the quantitative variables, such as age and sizes of the tumors, were reported. In addition, frequencies and percentages were presented for all categorical variables. To compare the frequency distribution in radiation therapy characteristics between functional and non‑functional tumors, the χ2 test or Fisher's exact test was applied, where appropriate. Kaplan‑Meier survival curve was drawn to assess the progression free survival proportion. P≤0.05 was considered to indicate a statistically significant difference. In the present study, all patients (n=75) with pituitary macroadenoma were treated with radiation therapy (RT). The mean age was 38.55±1.36 years and the majority of the patients were male (43; 57.3%). The mean tumor size was 3.84±1.43 cm. In total, 66.7% were non‑functional tumors whereas 33.3% were functional tumors that produce hormones in excess [growth hormone (72%), prolactin (16%), both growth hormone and prolactin (8%) and adrenocorticotropic hormone (4%)]. The overall outcome was revealed to be 92% achieving local tumor control and 28% achieving biochemical control. Hypopituitarism (38.7%) and visual acuity deterioration (9.3%) were the most common complications observed following RT. The overall progression‑free survival at 2 years was 92%. In conclusion, the data of the present study suggested that local tumor control in non‑functional and functional pituitary macroadenoma can be well managed with RT. However, biochemical control to normalize hormones overproduction in functional pituitary macroadenoma was not as effective as local tumor control.

View Figures

View References

1	Melmed S: Pathogenesis of pituitary tumors. Nat Rev Endocrinol. 7:257–266. 2011.PubMed/NCBI View Article : Google Scholar
2	Lim CT and Korbonits MK: Update on the clinicopathology of pituitary adenomas. Endocr Pract. 24:473–488. 2018.PubMed/NCBI View Article : Google Scholar
3	Brue T and Castinetti F: The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis. 11(135)2016.PubMed/NCBI View Article : Google Scholar
4	Russ S, Anastasopoulou C and Shafiq I: Pituitary adenoma. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2021.
5	Chin SO: Epidemiology of functioning pituitary adenomas. Endocrinol Metab (Seoul). 35:237–242. 2020.PubMed/NCBI View Article : Google Scholar
6	Hemminki K, Försti A and Ji J: Incidence and familial risks in pituitary adenoma and associated tumors. Endocr Relat Cancer. 14:103–109. 2007.PubMed/NCBI View Article : Google Scholar
7	Russ S, Anastasopoulou C and Shafiq I: Pituitary adenoma. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island, FL, 2022.
8	Molitch ME: Diagnosis and treatment of pituitary adenomas: A review. JAMA. 317:516–524. 2017.PubMed/NCBI View Article : Google Scholar
9	Ding D, Starke RM and Sheehan JP: Treatment paradigms for pituitary adenomas: Defining the roles of radiosurgery and radiation therapy. J Neurooncol. 117:445–457. 2014.PubMed/NCBI View Article : Google Scholar
10	Freda PU and Wardlaw SL: Clinical review 110: Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab. 84:3859–3866. 1999.PubMed/NCBI View Article : Google Scholar
11	Ciric I, Mikhael M, Stafford T, Lawson L and Garces R: Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. J Neurosurg. 59:395–401. 1983.PubMed/NCBI View Article : Google Scholar
12	Serioli S, Doglietto F, Fiorindi A, Biroli A, Mattavelli D, Buffoli B, Ferrari M, Cornali C, Rodella L, Maroldi R, et al: Pituitary adenomas and invasiveness from anatomo-surgical, radiological, and histological perspectives: A systematic literature review. Cancers (Basel). 11(1936)2019.PubMed/NCBI View Article : Google Scholar
13	Chanson P, Dormoy A and Dekkers OM: Use of radiotherapy after pituitary surgery for non-functioning pituitary adenomas. Eur J Endocrinol. 181:D1–D3. 2019.PubMed/NCBI View Article : Google Scholar
14	Scheick S, Amdur RJ, Kirwan JM, Morris CG, Mendenhall WM, Roper S and Friedman W: Long-term outcome after fractionated radiotherapy for pituitary adenoma: The curse of the secretory tumor. Am J Clin Oncol. 39:49–54. 2016.PubMed/NCBI View Article : Google Scholar
15	Sebastian P, Balakrishnan R, Yadav B and John S: Outcome of radiotherapy for pituitary adenomas. Rep Pract Oncol Radiother. 21:466–472. 2016.PubMed/NCBI View Article : Google Scholar
16	Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA and Kim CY: Radiotherapy for pituitary adenomas: Long-term outcome and complications. Radiat Oncol J. 29:156–163. 2011.PubMed/NCBI View Article : Google Scholar
17	Rutkowski M and Zada G: Management of pituitary adenomas invading the cavernous sinus. Neurosurg Clin N Am. 30:445–455. 2019.PubMed/NCBI View Article : Google Scholar
18	Loeffler J and Shih HA: Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab. 96:1992–2003. 2011.PubMed/NCBI View Article : Google Scholar
19	Langsenlehner T, Stiegler C, Quehenberger F, Feigl GC, Jakse G, Mokry M, Langsenlehner U, Kapp KS and Mayer R: Long-term follow-up of patients with pituitary macroadenomas after postoperative radiation therapy: Analysis of tumor control and functional outcome. Strahlenther Onkol. 183:241–247. 2007.PubMed/NCBI View Article : Google Scholar
20	Colin P, Jovenin N, Delemer B, Caron J, Grulet H, Hecart AC, Lukas C, Bazin A, Bernard MH, Scherpereel B, et al: Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: A prospective study of 110 patients. Int J Radiat Oncol Biol Phys. 62:333–341. 2005.PubMed/NCBI View Article : Google Scholar
21	Sasaki R, Murakami M, Okamoto Y, Kono K, Yoden E, Nakajima T, Nabeshima S and Kuroda Y: The efficacy of conventional radiation therapy in the management of pituitary adenoma. Int J Radiat Oncol Biol Phys. 47:1337–1345. 2000.PubMed/NCBI View Article : Google Scholar
22	Becker G, Kocher M, Kortmann RD, Paulsen F, Jeremic B, Müller RP and Bamberg M: Radiation therapy in the multimodal treatment approach of pituitary adenoma. Strahlenther Onkol. 178:173–186. 2002.PubMed/NCBI View Article : Google Scholar
23	Kokubo M, Sasai K, Shibamoto Y, Aoki T, Oya N, Mitsumori M, Takahashi JA, Hashimoto N and Hiraoka M: Long-term results of radiation therapy for pituitary adenoma. J Neurooncol. 47:79–84. 2000.PubMed/NCBI View Article : Google Scholar
24	Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G and Enrici RM: The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 62:210–216. 2005.PubMed/NCBI View Article : Google Scholar
25	Jallad RS, Musolino NR, Salgado LR and Bronstein MD: Treatment of acromegaly: Is there still a place for radiotherapy? Pituitary. 10:53–59. 2007.PubMed/NCBI View Article : Google Scholar
26	Wilson PJ, De-Loyde KJ, Williams JR and Smee RI: A single centre's experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the linear accelerator (Linac). J Clin Neurosci. 19:370–374. 2012.PubMed/NCBI View Article : Google Scholar
27	Gheorghiu ML and Fleseriu M: Stereotactic radiation therapy in pituitary adenomas, is it better than conventional radiation therapy? Acta Endocrinol (Buchar). 13:476–490. 2017.PubMed/NCBI View Article : Google Scholar